2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Cesar A. Santa-Maria, MD, discusses exploratory data seen with trastuzumab deruxtecan in patients with triple-negative breast cancer.
Cesar A. Santa-Maria, MD, assistant professor, oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses exploratory data seen with fam-trastuzumab deruxtecan-nxki (Enhertu) in patients with triple-negative breast cancer (TNBC).
Although the phase 3 DESTINY-Breast04 trial (NCT03734029) primarily studied trastuzumab deruxtecan in patients with estrogen receptor (ER)–positive, HER2-low unresectable or metastatic breast cancer, it also included a small cohort of 58 patients with TNBC, Santa-Maria says. In the ER-positive population, trastuzumab deruxtecan demonstrated remarkable efficacy, with a median progression-free survival (PFS) of 10.1 months and a median overall survival (OS) of 23.9 months, Santa-Maria explains.
This trial’s exploratory analysis of patients with TNBC showed survival benefits that mirrored those of the ER-positive population, with a median PFS of 8.5 months and a median OS of 18.2 months in the patients treated with trastuzumab deruxtecan, Santa-Marianotes. Trastuzumab deruxtecan is a potential treatment option for patients with TNBC, although further investigation is necessary to better understand the agent’s efficacy in this population, Santa-Maria concludes.